Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 9185 - 9192 of 12006 results

D.C. Circuit Holds "Boilerplate" Forward-Looking Statements Are Not Entitled to PSLRA's "Safe Harbor"
August 4, 2015| Blog| Viewpoint

The Affordable Care Act’s Reporting Requirements for Carriers and Employers: The Basics (Part 3 of 24)
August 4, 2015| Blog| Viewpoint

Obama Administration Unveils Clean Power Plan
August 4, 2015| Blog| Viewpoint

Massachusetts Appeals Court Set to Consider Scope of Employer Liability for Employee Data Breaches
August 4, 2015| Blog| Viewpoint

363 Sale Denied because Secured Creditor not Paid in Full from Proceeds
August 3, 2015| Blog| Viewpoint

West Virginia AG Clears Merger Creating Second Largest Hospital Chain in the State with Conduct Remedy
August 3, 2015| Alert| Viewpoint

Privacy Monday - August 3, 2015
August 3, 2015| Blog| Viewpoint
News & Press Releases
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.
Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts

Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|

Health Law Diagnosed: PBM Update Spring 2025
June 10, 2025| Podcast|
